Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery system. Vaxart vaccines are designed to be administered using convenient, room temperature-stable tablets that can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injury while helping to overcome vaccine hesitancy by avoiding needle-phobia issues. Vaxart believes its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication.
The Vaxart Value Proposition
Vaxart’s leaders and scientists explain how the little pill that moves the needle can have a significant impact on global public health.